We are live on ! Find out more
XBIT icon

XBiotech
XBIT

38 hedge funds and large institutions have $28.1M invested in XBiotech in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

394% more capital invested

Capital invested by funds: $5.68M → $28.1M (+$22.4M)

325% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 4

52% more funds holding

Funds holding: 25 → 38 (+13)

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

3.94% more ownership

Funds ownership: 3.12% → 7.06% (+3.9%)

72% less call options, than puts

Call options by funds: $387K | Put options by funds: $1.38M

Holders
38
Holders Change
+13
Holders Change %
+52%
% of All Funds
0.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
9
Reduced
7
Closed
4
Calls
$387K
Puts
$1.38M
Net Calls
-$988K
Net Calls Change
-$728K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.31M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$2.2M
3
SI
Sofinnova Investments
California
+$2.12M
4
Millennium Management
Millennium Management
New York
+$1.32M
5
Barclays
Barclays
United Kingdom
+$645K

Top Sellers

Rank Fund Capital Flow
1
EI
EAM Investors
California
-$286K
2
Group One Trading
Group One Trading
Illinois
-$114K
3
BFM
Boothbay Fund Management
New York
-$107K
4
VF
Virtu Financial
New York
-$80K
5
UBS Group
UBS Group
Switzerland
-$53K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$7.96M +$2.31M +285,154 +65%
Balyasny Asset Management
2
Balyasny Asset Management
Illinois
$3M +$2.2M +271,947 New
SI
3
Sofinnova Investments
California
$2.88M +$2.12M +261,391 New
Millennium Management
4
Millennium Management
New York
$2.34M +$1.32M +163,312 +333%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$1.83M +$249K +30,703 +23%
BlackRock
6
BlackRock
New York
$1.16M +$137K +16,907 +19%
EI
7
EAM Investors
California
$996K -$286K -35,216 -28%
Goldman Sachs
8
Goldman Sachs
New York
$896K +$578K +71,281 +710%
Barclays
9
Barclays
United Kingdom
$877K +$645K +79,544 +994,300%
TEE
10
Tibra Equities Europe
United Kingdom
$750K +$552K +68,047 New
Marshall Wace
11
Marshall Wace
United Kingdom
$682K +$502K +61,914 New
ECM
12
ExodusPoint Capital Management
New York
$590K +$434K +53,560 New
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$514K +$237K +29,179 +167%
Dimensional Fund Advisors
14
Dimensional Fund Advisors
Texas
$503K – – –
Northern Trust
15
Northern Trust
Illinois
$483K -$5.63K -695 -2%
BCM
16
BlueCrest Capital Management
Jersey
$303K +$223K +27,500 New
Citigroup
17
Citigroup
New York
$265K +$195K +24,049 New
State Street
18
State Street
Massachusetts
$251K -$2.8K -345 -1%
SB
19
Suntrust Banks
Georgia
$213K +$157K +19,353 New
SF
20
Synovus Financial
Georgia
$195K – – –
Bank of New York Mellon
21
Bank of New York Mellon
New York
$184K -$4.11K -507 -3%
Tudor Investment Corp
22
Tudor Investment Corp
Connecticut
$171K -$46.4K -5,726 -27%
Bank of America
23
Bank of America
North Carolina
$168K +$96.9K +11,947 +362%
JG
24
Jefferies Group
New York
$160K +$118K +14,500 New
Deutsche Bank
25
Deutsche Bank
Germany
$157K +$116K +14,331 New
1
2

XBIT Hedge Fund Activity: Q1 2019 in Review

38 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q1 2019, worth a combined $28.1M — up 394% from $5.68M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new XBIT positions and 4 closed out — a net gain of 13 holders — while 9 added to existing stakes and 7 trimmed.

The largest buyer was Vanguard Group, adding an estimated $2.31M. The largest seller was EAM Investors, cutting an estimated $286K.

  • 38 institutional investors held XBiotech (XBIT) as of Q1 2019, up from 25 in Q4 2018.
  • Funds reported $28.1M of XBiotech stock for Q1 2019, up 394% quarter-over-quarter.
  • 17 funds opened new XBiotech positions in Q1 2019 and 4 closed out, a net change of +13 holders.
  • The largest XBiotech buyer in Q1 2019 was Vanguard Group, an estimated $2.31M added.
  • The largest XBiotech seller in Q1 2019 was EAM Investors, an estimated $286K sold.

Based on aggregated 13F filings for Q1 2019.